- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
- 10-K Annual report
- 10.13 EX-10.13
- 10.16 EX-10.16
- 10.17 EX-10.17
- 10.20 EX-10.20
- 10.20.1 EX-10.20.1
- 10.20.2 EX-10.20.2
- 10.20.3 EX-10.20.3
- 10.20.4 EX-10.20.4
- 10.20.5 EX-10.20.5
- 10.20.6 EX-10.20.6
- 10.26 EX-10.26
- 21.1 EX-21.1
- 23.1 EX-23.1
- 23.2 EX-23.2
- 31.1 EX-31.1
- 31.2 EX-31.2
- 32.1 EX-32.1
- Download Excel data file
- View Excel data file
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of CRISPR Therapeutics AG (the “Company”) for the year ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned officers hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that to the best of his or her knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 8, 2018 |
| /s/ Samarth Kulkarni |
|
| Samarth Kulkarni |
|
| Chief Executive Officer |
|
| (Principal Executive Officer) |
Date: March 8, 2018 |
| /s/ Michael Tomsicek |
|
| Michael Tomsicek |
|
| Chief Financial Officer |
|
| (Principal Financial and Accounting Officer) |